TY - JOUR
T1 - Impact of elagolix on work loss due to endometriosis-associated pain
T2 - estimates based on the results of two phase III clinical trials
AU - Pokrzywinski, Robin M.
AU - Soliman, Ahmed M.
AU - Chen, Jun
AU - Snabes, Michael
AU - Diamond, Michael P.
AU - Surrey, Eric
AU - Coyne, Karin S.
PY - 2019/9
Y1 - 2019/9
N2 - Objective: To estimate the impact of elagolix on work loss due to endometriosis-associated pain. Design: Post hoc analysis of data from the Elaris I and II clinical trials. Setting: Not applicable. Patient(s): Employed women ages 18–49 years with moderate-to-severe endometriosis-associated pain. Intervention(s): In the two trials, participants were randomized to 6 months of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. Main Outcome Measure(s): Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire. Result(s): This analysis included employed participants from EM-I (n = 672) and EM-II (n = 626). Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 hours total work/week (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14). Participants treated with 200 mg twice a day gained > 4 hours total work/week (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14). Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism. Estimated cost savings after 6 months of treatment with elagolix were > $1,500 U.S. at 150 mg once a day and > $3,300 U.S. at 200 mg twice a day. Conclusion(s): Compared with placebo, treating moderate-to-severe endometriosis-associated pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings. Clinical Trial Number(s): NCT01620528 (EM-I) and NCT01931670 (EM-II).
AB - Objective: To estimate the impact of elagolix on work loss due to endometriosis-associated pain. Design: Post hoc analysis of data from the Elaris I and II clinical trials. Setting: Not applicable. Patient(s): Employed women ages 18–49 years with moderate-to-severe endometriosis-associated pain. Intervention(s): In the two trials, participants were randomized to 6 months of treatment with placebo, elagolix 150 mg once a day, or elagolix 200 mg twice a day. Main Outcome Measure(s): Data on planned work hours, presenteeism, absenteeism, and total work loss (absenteeism + presenteeism) at baseline and month 3 were collected using the Health-Related Productivity Questionnaire. Result(s): This analysis included employed participants from EM-I (n = 672) and EM-II (n = 626). Between baseline and month 3, compared with participants treated with placebo, participants treated with elagolix 150 mg once a day gained > 2 hours total work/week (EM-I, 2.20 ± 1.03; EM-II, 2.65 ± 1.14). Participants treated with 200 mg twice a day gained > 4 hours total work/week (EM-I, 4.91 ± 1.04; EM-II, 4.64 ± 1.14). Both absenteeism and presenteeism were reduced, although most of the gain was due to reduced presenteeism. Estimated cost savings after 6 months of treatment with elagolix were > $1,500 U.S. at 150 mg once a day and > $3,300 U.S. at 200 mg twice a day. Conclusion(s): Compared with placebo, treating moderate-to-severe endometriosis-associated pain with elagolix reduced absenteeism and improved productivity in employed women, which should result in cost savings. Clinical Trial Number(s): NCT01620528 (EM-I) and NCT01931670 (EM-II).
KW - absenteeism
KW - Endometriosis
KW - presenteeism
KW - productivity
UR - http://www.scopus.com/inward/record.url?scp=85067285131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067285131&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2019.04.031
DO - 10.1016/j.fertnstert.2019.04.031
M3 - Article
C2 - 31227284
AN - SCOPUS:85067285131
SN - 0015-0282
VL - 112
SP - 545
EP - 551
JO - Fertility and sterility
JF - Fertility and sterility
IS - 3
ER -